PerkinElmer strengthens screening portfolio business
This article was originally published in Clinica
Executive Summary
Health sciences firm PerkinElmer has expanded its presence in the genetic screening market with the acquisition of the newborn metabolic screening business of Pediatrix Medical Group. The deal sees PerkinElmer gain Sunrise, Florida-based Pediatrix's StepOne newborn screening product. StepOne can analyse up to 50 inherited disorders in newborn children, claims PerkinElmer, and has been used to screen more than three million babies since Pediatrix's inception in 1994. PerkinElmer will also acquire Pediatrix's metabolic screen laboratory, which provides neonatal screening and consultancy to hospitals and medical groups, as well as the whole of Maryland, Mississippi, Louisiana, Nebraska, Pennsylvania and the District of Columbia.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.